# Affymax, Inc. (AFFY)

> Source: Nexqual · https://nexqual.com/AFFY · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Affymax, Inc. (AFFY), nexqual.com/AFFY" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 22, 2026; US market closed, not a live price. Prev close 0 · day 0–0 · 52w 0–0.04 · market cap $60K · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y +77.8% vs S&P 500 +14.0%; 5Y -20.0% vs S&P 500 +76.9%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +77.8% | -20.0% |
| S&P 500 (SPY) | +14.0% | +76.9% |
| Per year | +78.4% | -4.4% |
| Volatility (annualized) | 721.2% | 464.6% |
| Max drawdown | -96.2% (Sep 2026→Sep 2026) | -99.6% (May 2022→Jun 2025) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/AFFY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2013-09-30) | — | — | — | $0 | — |
| Current fiscal year (ends 2013-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |